Researchers of Radboudumc have discovered that the iron in metal surgical implants can activate drugs such as antibiotics, thus enabling targeted therapy. With this method, antibiotics in the blood can target infections in the vicinity of an implant, write researchers Marja Bulte-ter Meer and Leo Schultze Kool in Chemical Communications.Metal implants are widely used in medical care, from artificial heart valves to trauma surgery and from dental prostheses to orthopedic surgery. However, the introduction of artificial tissue in the body entails a high risk of bacterial infection. As a result, patients with an implant often are required to use preventative antibiotics for long periods. This does not always have the desired effect, and can even be harmful, because these antibiotics are active throughout the body.
It is therefore more effective if drugs are active only in the vicinity of the implant, for example by administering the drug locally. One method to achieve this is known as enzyme-prodrug therapy (EPT). Patients receive inactive drugs – prodrugs – which can be converted into active drugs in the body. But for this work, the implant has to contain the enzymes needed for this conversion.
Discovered by accident
Marja Bulte-ter Meer, a PhD candidate working with Professor of Interventional Radiology Leo Schultze Kool of Radboudumc, discovered by accident that a certain type of widely used metal implant has an enzyme-like effect. This enables the implants to cleave sugar groups from molecules. This mechanism can be used for drug treatment by adding a sugar group to a drug, which results in a prodrug. As soon as the sugar group is cleaved from the molecule, the drug becomes active.
The researchers made their discovery when working with implants consisting of an alloy of cobalt, nickel, chromium and molybdenum. The implants themselves were inert, but a version with small grooves in the metal had strong activity in cleaving sugar groups. On closer inspection it appeared that iron had been deposited in these grooves. This iron turned out to be responsible for the efficient conversion of the drugs to their active form. The underlying mechanism for this process is not yet known.
Implants of pure iron would work best with enzyme-prodrug therapy. However, pure iron is chemically instable and cannot be used to make implants. The researchers therefore thought it would be a better idea to provide existing implants with an iron coating. Laboratory tests have shown that various implant materials with an iron coating can effectively convert an antibiotic pro-drug to an active drug.
During the past 18 months, Bulte-ter Meer and Schulze Kool have developed their discovery in collaboration with Aarhus University (Denmark) and implant manufacturer Fort Wayne Medical. The researchers have now applied for a patent on the enzymatic function of metallic implants. As a result, this technique can be used extensively for a wide range of drugs.
Marja Bulte - ter Meer is member of theme Rare cancers.
Leo Schultze Kool is member of theme Vascular damage.
Related news items
Imprinted genes during early embryonic development18 February 2019
René Dirks, with other members from the lab of Hendrik Marks, theme Cancer development and immune defense, show in a paper in Epigenetics & Chromatin that genomic imprinting (genes expressed from the paternal or maternal allele only) is often lost in cultured embryonic stem cells.read more
The first Radboud Nanomedicine community networking event14 February 2019
On 7 February 2019 the first Radboud Nanomedicine community networking event took place. The goal of the event was to bring together all those working in the field of nanomedicine at the Radboud University and Radboudumc, irrespective of the theme in which the research is performed.read more
Research Integrity Round: The ConScience App 15 February 201914 February 2019
To introduce the new Netherlands Code of Conduct for Research Integrity we invited ‘Het Acteursgenootschap’ to perform ‘The ConScience App’, a theatre piece designed to move the debate on scientific knowledge. All Radboudumc researchers are invited to attend this event.read more
Gene involved in colorectal cancer also causes breast cancer14 February 2019
Judith Grolleman, Nicoline Hoogerbrugge and Richarda de Voer, theme Tumors of the digestive tract, published in Cancer Cell that mutations in the NTHL1 gene, previously associated with colorectal cancer, also cause breast cancer and other types of cancer.read more
Endometrial natural killer cells remember previous pregnancy11 February 2019
Dorien Feyaerts, theme Inflammatory diseases, showed that pregnancy induces a memory phenotype on endometrial natural killer cells. However, previous CMV infection is a prerequisite for this memory induction. They published their findings in Cellular and Molecular Immunology.read more
ZonMw TOP grant to uncover the dormancy of malaria parasites7 February 2019
Richard Bartfai, theme Infectious diseases and global health, and Clemens Kocken (BPRC) received 675,000 euros from ZonMw to uncover the molecular mechanisms underlying dormancy of malaria parasites, a major obstacle to efficient treatment of P. vivax malaria.read more